nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Bimatoprost—glaucoma	0.414	1	CrCtD
Epoprostenol—PTGER1—Bimatoprost—glaucoma	0.174	0.896	CbGbCtD
Epoprostenol—Treprostinil—Latanoprost—glaucoma	0.08	0.27	CrCrCtD
Epoprostenol—Bimatoprost—Travoprost—glaucoma	0.0393	0.132	CrCrCtD
Epoprostenol—Dinoprost Tromethamine—Travoprost—glaucoma	0.0393	0.132	CrCrCtD
Epoprostenol—Dinoprost Tromethamine—Latanoprost—glaucoma	0.0365	0.123	CrCrCtD
Epoprostenol—Bimatoprost—Latanoprost—glaucoma	0.0365	0.123	CrCrCtD
Epoprostenol—Dinoprostone—Bimatoprost—glaucoma	0.0325	0.11	CrCrCtD
Epoprostenol—Dinoprost Tromethamine—Bimatoprost—glaucoma	0.0325	0.11	CrCrCtD
Epoprostenol—CYP2C9—Diclofenamide—glaucoma	0.0071	0.0367	CbGbCtD
Epoprostenol—CYP2C9—Dorzolamide—glaucoma	0.00686	0.0354	CbGbCtD
Epoprostenol—CYP2C9—Methazolamide—glaucoma	0.00611	0.0316	CbGbCtD
Epoprostenol—Bimatoprost—PTGFR—glaucoma	0.000989	0.483	CrCbGaD
Epoprostenol—PTGIS—endothelium—glaucoma	0.000654	0.431	CbGeAlD
Epoprostenol—Dinoprost Tromethamine—PTGFR—glaucoma	0.000599	0.292	CrCbGaD
Epoprostenol—Dinoprostone—PTGFR—glaucoma	0.000461	0.225	CrCbGaD
Epoprostenol—PTGIR—endothelium—glaucoma	0.000375	0.248	CbGeAlD
Epoprostenol—PTGIS—connective tissue—glaucoma	0.000309	0.204	CbGeAlD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000273	0.00841	CbGpPWpGaD
Epoprostenol—PTGIS—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000265	0.00816	CbGpPWpGaD
Epoprostenol—PTGIR—Endothelin Pathways—EDN1—glaucoma	0.000253	0.00779	CbGpPWpGaD
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGS2—glaucoma	0.000249	0.00766	CbGpPWpGaD
Epoprostenol—PTGIS—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000215	0.00662	CbGpPWpGaD
Epoprostenol—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.000215	0.00661	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—OPN4—glaucoma	0.000211	0.0065	CbGpPWpGaD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	0.000208	0.0064	CbGpPWpGaD
Epoprostenol—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.000195	0.00602	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000194	0.00597	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—PTGFR—glaucoma	0.00019	0.00585	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.000189	0.00581	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000178	0.00549	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000178	0.00549	CbGpPWpGaD
Epoprostenol—PTGIR—connective tissue—glaucoma	0.000177	0.117	CbGeAlD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000177	0.00546	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00017	0.00524	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000163	0.00503	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000163	0.00503	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.00016	0.00492	CbGpPWpGaD
Epoprostenol—PTGIR—Endothelin Pathways—NOS3—glaucoma	0.000154	0.00475	CbGpPWpGaD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	0.000152	0.00469	CbGpPWpGaD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	0.000152	0.00469	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000152	0.00468	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000147	0.00452	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000147	0.00452	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—GSTT1—glaucoma	0.000143	0.00441	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.00014	0.00431	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.00014	0.00431	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	0.000139	0.00428	CbGpPWpGaD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PTGS2—glaucoma	0.000138	0.00426	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000137	0.00421	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000126	0.00388	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000126	0.00388	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—OPN4—glaucoma	0.000116	0.00356	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—CYP1B1—glaucoma	0.000114	0.00351	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000107	0.00328	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—OPN4—glaucoma	0.000106	0.00328	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—OPN4—glaucoma	0.000106	0.00328	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—NR3C1—glaucoma	0.000106	0.00325	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—PTGFR—glaucoma	0.000104	0.00321	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—FAS—glaucoma	0.000102	0.00315	CbGpPWpGaD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—NOS3—glaucoma	0.000101	0.00311	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CA5A—glaucoma	0.0001	0.00309	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NARFL—glaucoma	0.0001	0.00309	CbGpPWpGaD
Epoprostenol—CYP2C9—Tamoxifen metabolism—CYP1B1—glaucoma	9.92e-05	0.00305	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—PTGFR—glaucoma	9.58e-05	0.00295	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—PTGFR—glaucoma	9.58e-05	0.00295	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—GSTM1—glaucoma	9.12e-05	0.00281	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—LRP12—glaucoma	9.08e-05	0.0028	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—glaucoma	8.87e-05	0.00273	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—TGFB2—glaucoma	8.73e-05	0.00269	CbGpPWpGaD
Epoprostenol—PTGIR—Platelet homeostasis—NOS3—glaucoma	7.75e-05	0.00239	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	6.75e-05	0.00208	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—SOD1—glaucoma	6.62e-05	0.00204	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—OPN4—glaucoma	6.54e-05	0.00201	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—EDN1—glaucoma	6.32e-05	0.00195	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—OPN4—glaucoma	6.02e-05	0.00185	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—OPN4—glaucoma	6.02e-05	0.00185	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—OPN4—glaucoma	5.94e-05	0.00183	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PTGFR—glaucoma	5.89e-05	0.00181	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HEYL—glaucoma	5.85e-05	0.0018	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—FGFR1OP—glaucoma	5.85e-05	0.0018	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	5.65e-05	0.00174	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—OPN4—glaucoma	5.46e-05	0.00168	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—OPN4—glaucoma	5.46e-05	0.00168	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PTGFR—glaucoma	5.42e-05	0.00167	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PTGFR—glaucoma	5.42e-05	0.00167	CbGpPWpGaD
Epoprostenol—Flushing—Betaxolol—glaucoma	5.35e-05	0.000902	CcSEcCtD
Epoprostenol—Cardiac disorder—Betaxolol—glaucoma	5.35e-05	0.000902	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PTGFR—glaucoma	5.34e-05	0.00165	CbGpPWpGaD
Epoprostenol—Pain—Dorzolamide—glaucoma	5.33e-05	0.000899	CcSEcCtD
Epoprostenol—Insomnia—Pilocarpine—glaucoma	5.32e-05	0.000898	CcSEcCtD
Epoprostenol—Decreased appetite—Brinzolamide—glaucoma	5.32e-05	0.000898	CcSEcCtD
Epoprostenol—Weight decreased—Timolol—glaucoma	5.32e-05	0.000897	CcSEcCtD
Epoprostenol—Pain—Travoprost—glaucoma	5.3e-05	0.000895	CcSEcCtD
Epoprostenol—Constipation—Travoprost—glaucoma	5.3e-05	0.000895	CcSEcCtD
Epoprostenol—Agitation—Clonidine—glaucoma	5.29e-05	0.000893	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Brinzolamide—glaucoma	5.29e-05	0.000892	CcSEcCtD
Epoprostenol—Paraesthesia—Pilocarpine—glaucoma	5.29e-05	0.000892	CcSEcCtD
Epoprostenol—Asthenia—Bimatoprost—glaucoma	5.29e-05	0.000892	CcSEcCtD
Epoprostenol—Fatigue—Brinzolamide—glaucoma	5.28e-05	0.000891	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—SMO—glaucoma	5.25e-05	0.00162	CbGpPWpGaD
Epoprostenol—Dyspnoea—Pilocarpine—glaucoma	5.25e-05	0.000885	CcSEcCtD
Epoprostenol—Pain—Brinzolamide—glaucoma	5.24e-05	0.000884	CcSEcCtD
Epoprostenol—Somnolence—Pilocarpine—glaucoma	5.23e-05	0.000883	CcSEcCtD
Epoprostenol—Depression—Timolol—glaucoma	5.23e-05	0.000882	CcSEcCtD
Epoprostenol—Angiopathy—Betaxolol—glaucoma	5.23e-05	0.000882	CcSEcCtD
Epoprostenol—Pruritus—Bimatoprost—glaucoma	5.21e-05	0.000879	CcSEcCtD
Epoprostenol—Diarrhoea—Apraclonidine—glaucoma	5.2e-05	0.000877	CcSEcCtD
Epoprostenol—Mediastinal disorder—Betaxolol—glaucoma	5.19e-05	0.000876	CcSEcCtD
Epoprostenol—Dyspepsia—Pilocarpine—glaucoma	5.18e-05	0.000874	CcSEcCtD
Epoprostenol—Chills—Betaxolol—glaucoma	5.17e-05	0.000872	CcSEcCtD
Epoprostenol—Syncope—Clonidine—glaucoma	5.17e-05	0.000872	CcSEcCtD
Epoprostenol—Decreased appetite—Pilocarpine—glaucoma	5.12e-05	0.000863	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Dorzolamide—glaucoma	5.09e-05	0.00086	CcSEcCtD
Epoprostenol—Palpitations—Clonidine—glaucoma	5.09e-05	0.000859	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Pilocarpine—glaucoma	5.08e-05	0.000857	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Travoprost—glaucoma	5.07e-05	0.000856	CcSEcCtD
Epoprostenol—Loss of consciousness—Clonidine—glaucoma	5.06e-05	0.000854	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—LRP12—glaucoma	5.06e-05	0.00156	CbGpPWpGaD
Epoprostenol—Mental disorder—Betaxolol—glaucoma	5.05e-05	0.000852	CcSEcCtD
Epoprostenol—Pain—Pilocarpine—glaucoma	5.03e-05	0.000849	CcSEcCtD
Epoprostenol—Constipation—Pilocarpine—glaucoma	5.03e-05	0.000849	CcSEcCtD
Epoprostenol—Cough—Clonidine—glaucoma	5.03e-05	0.000848	CcSEcCtD
Epoprostenol—Sweating—Timolol—glaucoma	5.03e-05	0.000848	CcSEcCtD
Epoprostenol—Dizziness—Apraclonidine—glaucoma	5.03e-05	0.000848	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—C3—glaucoma	5e-05	0.00154	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—CYP1B1—glaucoma	4.95e-05	0.00153	CbGpPWpGaD
Epoprostenol—Urticaria—Dorzolamide—glaucoma	4.95e-05	0.000835	CcSEcCtD
Epoprostenol—Epistaxis—Timolol—glaucoma	4.95e-05	0.000834	CcSEcCtD
Epoprostenol—Body temperature increased—Dorzolamide—glaucoma	4.93e-05	0.000831	CcSEcCtD
Epoprostenol—Abdominal pain—Dorzolamide—glaucoma	4.93e-05	0.000831	CcSEcCtD
Epoprostenol—Tension—Betaxolol—glaucoma	4.92e-05	0.00083	CcSEcCtD
Epoprostenol—Sinusitis—Timolol—glaucoma	4.92e-05	0.00083	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—PTGFR—glaucoma	4.92e-05	0.00151	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PTGFR—glaucoma	4.92e-05	0.00151	CbGpPWpGaD
Epoprostenol—Arthralgia—Clonidine—glaucoma	4.9e-05	0.000827	CcSEcCtD
Epoprostenol—Chest pain—Clonidine—glaucoma	4.9e-05	0.000827	CcSEcCtD
Epoprostenol—Abdominal pain—Travoprost—glaucoma	4.9e-05	0.000827	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CA1—glaucoma	4.9e-05	0.00151	CbGpPWpGaD
Epoprostenol—Anxiety—Clonidine—glaucoma	4.89e-05	0.000825	CcSEcCtD
Epoprostenol—Asthenia—Acetazolamide—glaucoma	4.88e-05	0.000823	CcSEcCtD
Epoprostenol—Dizziness—Bimatoprost—glaucoma	4.87e-05	0.000822	CcSEcCtD
Epoprostenol—Nervousness—Betaxolol—glaucoma	4.87e-05	0.000822	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	4.87e-05	0.000822	CcSEcCtD
Epoprostenol—Urticaria—Brinzolamide—glaucoma	4.87e-05	0.000821	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—SMO—glaucoma	4.83e-05	0.00149	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—SMO—glaucoma	4.83e-05	0.00149	CbGpPWpGaD
Epoprostenol—Vomiting—Apraclonidine—glaucoma	4.83e-05	0.000815	CcSEcCtD
Epoprostenol—Muscle spasms—Betaxolol—glaucoma	4.82e-05	0.000813	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Pilocarpine—glaucoma	4.81e-05	0.000812	CcSEcCtD
Epoprostenol—Hypersensitivity—Brimonidine—glaucoma	4.81e-05	0.000811	CcSEcCtD
Epoprostenol—Dry mouth—Clonidine—glaucoma	4.8e-05	0.000809	CcSEcCtD
Epoprostenol—Bradycardia—Timolol—glaucoma	4.79e-05	0.000808	CcSEcCtD
Epoprostenol—Dermatitis—Apraclonidine—glaucoma	4.79e-05	0.000808	CcSEcCtD
Epoprostenol—Headache—Apraclonidine—glaucoma	4.76e-05	0.000803	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CTSA—glaucoma	4.75e-05	0.00146	CbGpPWpGaD
Epoprostenol—Confusional state—Clonidine—glaucoma	4.74e-05	0.0008	CcSEcCtD
Epoprostenol—Rhinitis—Timolol—glaucoma	4.72e-05	0.000796	CcSEcCtD
Epoprostenol—Oedema—Clonidine—glaucoma	4.7e-05	0.000793	CcSEcCtD
Epoprostenol—Tremor—Betaxolol—glaucoma	4.7e-05	0.000793	CcSEcCtD
Epoprostenol—Asthenia—Brimonidine—glaucoma	4.68e-05	0.00079	CcSEcCtD
Epoprostenol—Infection—Clonidine—glaucoma	4.67e-05	0.000788	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—LRP12—glaucoma	4.66e-05	0.00143	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LRP12—glaucoma	4.66e-05	0.00143	CbGpPWpGaD
Epoprostenol—Abdominal pain—Pilocarpine—glaucoma	4.65e-05	0.000785	CcSEcCtD
Epoprostenol—Body temperature increased—Pilocarpine—glaucoma	4.65e-05	0.000785	CcSEcCtD
Epoprostenol—Diarrhoea—Acetazolamide—glaucoma	4.65e-05	0.000785	CcSEcCtD
Epoprostenol—Rash—Bimatoprost—glaucoma	4.65e-05	0.000784	CcSEcCtD
Epoprostenol—Dermatitis—Bimatoprost—glaucoma	4.64e-05	0.000783	CcSEcCtD
Epoprostenol—Oedema peripheral—Timolol—glaucoma	4.64e-05	0.000782	CcSEcCtD
Epoprostenol—Anaemia—Betaxolol—glaucoma	4.64e-05	0.000782	CcSEcCtD
Epoprostenol—Shock—Clonidine—glaucoma	4.63e-05	0.00078	CcSEcCtD
Epoprostenol—Connective tissue disorder—Timolol—glaucoma	4.62e-05	0.00078	CcSEcCtD
Epoprostenol—Pruritus—Brimonidine—glaucoma	4.62e-05	0.000779	CcSEcCtD
Epoprostenol—Headache—Bimatoprost—glaucoma	4.62e-05	0.000779	CcSEcCtD
Epoprostenol—Nervous system disorder—Clonidine—glaucoma	4.61e-05	0.000778	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—FN1—glaucoma	4.61e-05	0.00142	CbGpPWpGaD
Epoprostenol—Thrombocytopenia—Clonidine—glaucoma	4.6e-05	0.000777	CcSEcCtD
Epoprostenol—Hypersensitivity—Dorzolamide—glaucoma	4.59e-05	0.000774	CcSEcCtD
Epoprostenol—Tachycardia—Clonidine—glaucoma	4.59e-05	0.000774	CcSEcCtD
Epoprostenol—Hypersensitivity—Travoprost—glaucoma	4.57e-05	0.000771	CcSEcCtD
Epoprostenol—Skin disorder—Clonidine—glaucoma	4.57e-05	0.00077	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	4.55e-05	0.0014	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Clonidine—glaucoma	4.54e-05	0.000767	CcSEcCtD
Epoprostenol—Nausea—Apraclonidine—glaucoma	4.51e-05	0.000762	CcSEcCtD
Epoprostenol—Hypersensitivity—Brinzolamide—glaucoma	4.51e-05	0.000761	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—TGFB2—glaucoma	4.5e-05	0.00139	CbGpPWpGaD
Epoprostenol—Syncope—Betaxolol—glaucoma	4.5e-05	0.000759	CcSEcCtD
Epoprostenol—Dizziness—Acetazolamide—glaucoma	4.49e-05	0.000758	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CA2—glaucoma	4.48e-05	0.00138	CbGpPWpGaD
Epoprostenol—Anorexia—Clonidine—glaucoma	4.48e-05	0.000756	CcSEcCtD
Epoprostenol—Asthenia—Dorzolamide—glaucoma	4.47e-05	0.000754	CcSEcCtD
Epoprostenol—Asthenia—Travoprost—glaucoma	4.45e-05	0.000751	CcSEcCtD
Epoprostenol—Palpitations—Betaxolol—glaucoma	4.43e-05	0.000748	CcSEcCtD
Epoprostenol—Pruritus—Dorzolamide—glaucoma	4.41e-05	0.000744	CcSEcCtD
Epoprostenol—Loss of consciousness—Betaxolol—glaucoma	4.41e-05	0.000744	CcSEcCtD
Epoprostenol—Asthenia—Brinzolamide—glaucoma	4.39e-05	0.000741	CcSEcCtD
Epoprostenol—Hypotension—Clonidine—glaucoma	4.39e-05	0.000741	CcSEcCtD
Epoprostenol—Pruritus—Travoprost—glaucoma	4.39e-05	0.00074	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	4.38e-05	0.00135	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	4.38e-05	0.00135	CbGpPWpGaD
Epoprostenol—Cough—Betaxolol—glaucoma	4.38e-05	0.000738	CcSEcCtD
Epoprostenol—Nausea—Bimatoprost—glaucoma	4.38e-05	0.000738	CcSEcCtD
Epoprostenol—Cardiac disorder—Timolol—glaucoma	4.37e-05	0.000737	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—TNF—glaucoma	4.34e-05	0.00134	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Pilocarpine—glaucoma	4.34e-05	0.000732	CcSEcCtD
Epoprostenol—Pruritus—Brinzolamide—glaucoma	4.33e-05	0.000731	CcSEcCtD
Epoprostenol—Vomiting—Acetazolamide—glaucoma	4.32e-05	0.000729	CcSEcCtD
Epoprostenol—Dizziness—Brimonidine—glaucoma	4.31e-05	0.000728	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Clonidine—glaucoma	4.28e-05	0.000723	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	4.28e-05	0.00132	CbGpPWpGaD
Epoprostenol—Angiopathy—Timolol—glaucoma	4.27e-05	0.00072	CcSEcCtD
Epoprostenol—Myalgia—Betaxolol—glaucoma	4.27e-05	0.00072	CcSEcCtD
Epoprostenol—Arthralgia—Betaxolol—glaucoma	4.27e-05	0.00072	CcSEcCtD
Epoprostenol—Chest pain—Betaxolol—glaucoma	4.27e-05	0.00072	CcSEcCtD
Epoprostenol—Diarrhoea—Dorzolamide—glaucoma	4.26e-05	0.000719	CcSEcCtD
Epoprostenol—Headache—Acetazolamide—glaucoma	4.26e-05	0.000718	CcSEcCtD
Epoprostenol—Anxiety—Betaxolol—glaucoma	4.25e-05	0.000718	CcSEcCtD
Epoprostenol—Insomnia—Clonidine—glaucoma	4.25e-05	0.000717	CcSEcCtD
Epoprostenol—Diarrhoea—Travoprost—glaucoma	4.24e-05	0.000716	CcSEcCtD
Epoprostenol—Mediastinal disorder—Timolol—glaucoma	4.24e-05	0.000716	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	4.24e-05	0.000715	CcSEcCtD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—glaucoma	4.23e-05	0.0013	CbGpPWpGaD
Epoprostenol—Asthenia—Pilocarpine—glaucoma	4.22e-05	0.000713	CcSEcCtD
Epoprostenol—Paraesthesia—Clonidine—glaucoma	4.22e-05	0.000712	CcSEcCtD
Epoprostenol—Dyspnoea—Clonidine—glaucoma	4.19e-05	0.000707	CcSEcCtD
Epoprostenol—Diarrhoea—Brinzolamide—glaucoma	4.19e-05	0.000707	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	4.18e-05	0.00129	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	4.18e-05	0.00129	CbGpPWpGaD
Epoprostenol—Somnolence—Clonidine—glaucoma	4.18e-05	0.000705	CcSEcCtD
Epoprostenol—Dry mouth—Betaxolol—glaucoma	4.18e-05	0.000704	CcSEcCtD
Epoprostenol—Pruritus—Pilocarpine—glaucoma	4.17e-05	0.000703	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—TGFB2—glaucoma	4.14e-05	0.00128	CbGpPWpGaD
Epoprostenol—Confusional state—Betaxolol—glaucoma	4.13e-05	0.000696	CcSEcCtD
Epoprostenol—Mental disorder—Timolol—glaucoma	4.12e-05	0.000696	CcSEcCtD
Epoprostenol—Dizziness—Dorzolamide—glaucoma	4.12e-05	0.000695	CcSEcCtD
Epoprostenol—Rash—Brimonidine—glaucoma	4.11e-05	0.000694	CcSEcCtD
Epoprostenol—Dermatitis—Brimonidine—glaucoma	4.11e-05	0.000693	CcSEcCtD
Epoprostenol—Dizziness—Travoprost—glaucoma	4.1e-05	0.000692	CcSEcCtD
Epoprostenol—Oedema—Betaxolol—glaucoma	4.09e-05	0.000691	CcSEcCtD
Epoprostenol—Headache—Brimonidine—glaucoma	4.09e-05	0.00069	CcSEcCtD
Epoprostenol—Decreased appetite—Clonidine—glaucoma	4.09e-05	0.000689	CcSEcCtD
Epoprostenol—Infection—Betaxolol—glaucoma	4.07e-05	0.000686	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Clonidine—glaucoma	4.06e-05	0.000685	CcSEcCtD
Epoprostenol—Fatigue—Clonidine—glaucoma	4.05e-05	0.000684	CcSEcCtD
Epoprostenol—Dizziness—Brinzolamide—glaucoma	4.05e-05	0.000683	CcSEcCtD
Epoprostenol—Nausea—Acetazolamide—glaucoma	4.04e-05	0.000681	CcSEcCtD
Epoprostenol—Diarrhoea—Pilocarpine—glaucoma	4.03e-05	0.00068	CcSEcCtD
Epoprostenol—Shock—Betaxolol—glaucoma	4.03e-05	0.000679	CcSEcCtD
Epoprostenol—Tension—Timolol—glaucoma	4.02e-05	0.000678	CcSEcCtD
Epoprostenol—Pain—Clonidine—glaucoma	4.02e-05	0.000678	CcSEcCtD
Epoprostenol—Constipation—Clonidine—glaucoma	4.02e-05	0.000678	CcSEcCtD
Epoprostenol—Nervous system disorder—Betaxolol—glaucoma	4.01e-05	0.000677	CcSEcCtD
Epoprostenol—Thrombocytopenia—Betaxolol—glaucoma	4.01e-05	0.000676	CcSEcCtD
Epoprostenol—Tachycardia—Betaxolol—glaucoma	3.99e-05	0.000674	CcSEcCtD
Epoprostenol—Nervousness—Timolol—glaucoma	3.98e-05	0.000671	CcSEcCtD
Epoprostenol—Skin disorder—Betaxolol—glaucoma	3.98e-05	0.000671	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	3.97e-05	0.00122	CbGpPWpGaD
Epoprostenol—Vomiting—Dorzolamide—glaucoma	3.96e-05	0.000668	CcSEcCtD
Epoprostenol—Hyperhidrosis—Betaxolol—glaucoma	3.96e-05	0.000668	CcSEcCtD
Epoprostenol—Rash—Dorzolamide—glaucoma	3.93e-05	0.000663	CcSEcCtD
Epoprostenol—Dermatitis—Dorzolamide—glaucoma	3.92e-05	0.000662	CcSEcCtD
Epoprostenol—Rash—Travoprost—glaucoma	3.91e-05	0.00066	CcSEcCtD
Epoprostenol—Dermatitis—Travoprost—glaucoma	3.91e-05	0.000659	CcSEcCtD
Epoprostenol—Headache—Dorzolamide—glaucoma	3.9e-05	0.000658	CcSEcCtD
Epoprostenol—Anorexia—Betaxolol—glaucoma	3.9e-05	0.000658	CcSEcCtD
Epoprostenol—Vomiting—Brinzolamide—glaucoma	3.89e-05	0.000657	CcSEcCtD
Epoprostenol—Dizziness—Pilocarpine—glaucoma	3.89e-05	0.000657	CcSEcCtD
Epoprostenol—Headache—Travoprost—glaucoma	3.89e-05	0.000656	CcSEcCtD
Epoprostenol—Nausea—Brimonidine—glaucoma	3.88e-05	0.000654	CcSEcCtD
Epoprostenol—Rash—Brinzolamide—glaucoma	3.86e-05	0.000652	CcSEcCtD
Epoprostenol—Dermatitis—Brinzolamide—glaucoma	3.86e-05	0.000651	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Clonidine—glaucoma	3.84e-05	0.000649	CcSEcCtD
Epoprostenol—Headache—Brinzolamide—glaucoma	3.84e-05	0.000647	CcSEcCtD
Epoprostenol—Hypotension—Betaxolol—glaucoma	3.82e-05	0.000645	CcSEcCtD
Epoprostenol—Vomiting—Pilocarpine—glaucoma	3.74e-05	0.000632	CcSEcCtD
Epoprostenol—Urticaria—Clonidine—glaucoma	3.73e-05	0.00063	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Betaxolol—glaucoma	3.73e-05	0.000629	CcSEcCtD
Epoprostenol—Abdominal pain—Clonidine—glaucoma	3.72e-05	0.000627	CcSEcCtD
Epoprostenol—Body temperature increased—Clonidine—glaucoma	3.72e-05	0.000627	CcSEcCtD
Epoprostenol—Rash—Pilocarpine—glaucoma	3.71e-05	0.000626	CcSEcCtD
Epoprostenol—Dermatitis—Pilocarpine—glaucoma	3.71e-05	0.000626	CcSEcCtD
Epoprostenol—Insomnia—Betaxolol—glaucoma	3.7e-05	0.000625	CcSEcCtD
Epoprostenol—Nausea—Dorzolamide—glaucoma	3.7e-05	0.000624	CcSEcCtD
Epoprostenol—Headache—Pilocarpine—glaucoma	3.69e-05	0.000622	CcSEcCtD
Epoprostenol—Nausea—Travoprost—glaucoma	3.68e-05	0.000622	CcSEcCtD
Epoprostenol—Paraesthesia—Betaxolol—glaucoma	3.68e-05	0.00062	CcSEcCtD
Epoprostenol—Syncope—Timolol—glaucoma	3.67e-05	0.00062	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	3.66e-05	0.00113	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	3.66e-05	0.00113	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HDAC9—glaucoma	3.65e-05	0.00113	CbGpPWpGaD
Epoprostenol—Dyspnoea—Betaxolol—glaucoma	3.65e-05	0.000616	CcSEcCtD
Epoprostenol—Nausea—Brinzolamide—glaucoma	3.64e-05	0.000614	CcSEcCtD
Epoprostenol—Palpitations—Timolol—glaucoma	3.62e-05	0.000611	CcSEcCtD
Epoprostenol—Dyspepsia—Betaxolol—glaucoma	3.6e-05	0.000608	CcSEcCtD
Epoprostenol—Loss of consciousness—Timolol—glaucoma	3.6e-05	0.000608	CcSEcCtD
Epoprostenol—Cough—Timolol—glaucoma	3.58e-05	0.000603	CcSEcCtD
Epoprostenol—Decreased appetite—Betaxolol—glaucoma	3.56e-05	0.0006	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Betaxolol—glaucoma	3.53e-05	0.000596	CcSEcCtD
Epoprostenol—Fatigue—Betaxolol—glaucoma	3.53e-05	0.000595	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—OPN4—glaucoma	3.51e-05	0.00108	CbGpPWpGaD
Epoprostenol—Pain—Betaxolol—glaucoma	3.5e-05	0.000591	CcSEcCtD
Epoprostenol—Constipation—Betaxolol—glaucoma	3.5e-05	0.000591	CcSEcCtD
Epoprostenol—Nausea—Pilocarpine—glaucoma	3.5e-05	0.00059	CcSEcCtD
Epoprostenol—Myalgia—Timolol—glaucoma	3.49e-05	0.000588	CcSEcCtD
Epoprostenol—Arthralgia—Timolol—glaucoma	3.49e-05	0.000588	CcSEcCtD
Epoprostenol—Chest pain—Timolol—glaucoma	3.49e-05	0.000588	CcSEcCtD
Epoprostenol—Anxiety—Timolol—glaucoma	3.48e-05	0.000586	CcSEcCtD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	3.47e-05	0.00107	CbGpPWpGaD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	3.46e-05	0.000584	CcSEcCtD
Epoprostenol—Hypersensitivity—Clonidine—glaucoma	3.46e-05	0.000584	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—EDN1—glaucoma	3.46e-05	0.00107	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SOD1—glaucoma	3.41e-05	0.00105	CbGpPWpGaD
Epoprostenol—Dry mouth—Timolol—glaucoma	3.41e-05	0.000576	CcSEcCtD
Epoprostenol—Asthenia—Clonidine—glaucoma	3.37e-05	0.000569	CcSEcCtD
Epoprostenol—Confusional state—Timolol—glaucoma	3.37e-05	0.000569	CcSEcCtD
Epoprostenol—Oedema—Timolol—glaucoma	3.34e-05	0.000564	CcSEcCtD
Epoprostenol—Anaphylactic shock—Timolol—glaucoma	3.34e-05	0.000564	CcSEcCtD
Epoprostenol—Pruritus—Clonidine—glaucoma	3.33e-05	0.000561	CcSEcCtD
Epoprostenol—Infection—Timolol—glaucoma	3.32e-05	0.00056	CcSEcCtD
Epoprostenol—Shock—Timolol—glaucoma	3.29e-05	0.000555	CcSEcCtD
Epoprostenol—Nervous system disorder—Timolol—glaucoma	3.28e-05	0.000553	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—HEYL—glaucoma	3.26e-05	0.001	CbGpPWpGaD
Epoprostenol—Urticaria—Betaxolol—glaucoma	3.25e-05	0.000549	CcSEcCtD
Epoprostenol—Skin disorder—Timolol—glaucoma	3.25e-05	0.000548	CcSEcCtD
Epoprostenol—Body temperature increased—Betaxolol—glaucoma	3.24e-05	0.000546	CcSEcCtD
Epoprostenol—Hyperhidrosis—Timolol—glaucoma	3.23e-05	0.000545	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—OPN4—glaucoma	3.23e-05	0.000994	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—OPN4—glaucoma	3.23e-05	0.000994	CbGpPWpGaD
Epoprostenol—Diarrhoea—Clonidine—glaucoma	3.22e-05	0.000543	CcSEcCtD
Epoprostenol—Anorexia—Timolol—glaucoma	3.19e-05	0.000538	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—EDN1—glaucoma	3.19e-05	0.000981	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—EDN1—glaucoma	3.19e-05	0.000981	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TXN—glaucoma	3.16e-05	0.000973	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTGFR—glaucoma	3.16e-05	0.000972	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SOD1—glaucoma	3.14e-05	0.000967	CbGpPWpGaD
Epoprostenol—Hypotension—Timolol—glaucoma	3.12e-05	0.000527	CcSEcCtD
Epoprostenol—Dizziness—Clonidine—glaucoma	3.11e-05	0.000525	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Timolol—glaucoma	3.05e-05	0.000514	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—C3—glaucoma	3.02e-05	0.000932	CbGpPWpGaD
Epoprostenol—Insomnia—Timolol—glaucoma	3.02e-05	0.00051	CcSEcCtD
Epoprostenol—Hypersensitivity—Betaxolol—glaucoma	3.02e-05	0.000509	CcSEcCtD
Epoprostenol—Paraesthesia—Timolol—glaucoma	3e-05	0.000507	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—HEYL—glaucoma	3e-05	0.000924	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HEYL—glaucoma	3e-05	0.000924	CbGpPWpGaD
Epoprostenol—Vomiting—Clonidine—glaucoma	2.99e-05	0.000504	CcSEcCtD
Epoprostenol—Dyspnoea—Timolol—glaucoma	2.98e-05	0.000503	CcSEcCtD
Epoprostenol—Somnolence—Timolol—glaucoma	2.97e-05	0.000502	CcSEcCtD
Epoprostenol—Rash—Clonidine—glaucoma	2.96e-05	0.0005	CcSEcCtD
Epoprostenol—Dermatitis—Clonidine—glaucoma	2.96e-05	0.0005	CcSEcCtD
Epoprostenol—Headache—Clonidine—glaucoma	2.95e-05	0.000497	CcSEcCtD
Epoprostenol—Dyspepsia—Timolol—glaucoma	2.94e-05	0.000497	CcSEcCtD
Epoprostenol—Asthenia—Betaxolol—glaucoma	2.94e-05	0.000495	CcSEcCtD
Epoprostenol—Decreased appetite—Timolol—glaucoma	2.91e-05	0.00049	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—PTGFR—glaucoma	2.91e-05	0.000895	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTGFR—glaucoma	2.91e-05	0.000895	CbGpPWpGaD
Epoprostenol—Pruritus—Betaxolol—glaucoma	2.9e-05	0.000489	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Timolol—glaucoma	2.89e-05	0.000487	CcSEcCtD
Epoprostenol—Fatigue—Timolol—glaucoma	2.88e-05	0.000486	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.88e-05	0.000888	CbGpPWpGaD
Epoprostenol—Pain—Timolol—glaucoma	2.86e-05	0.000482	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.86e-05	0.00088	CbGpPWpGaD
Epoprostenol—Diarrhoea—Betaxolol—glaucoma	2.8e-05	0.000472	CcSEcCtD
Epoprostenol—Nausea—Clonidine—glaucoma	2.79e-05	0.000471	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—C3—glaucoma	2.78e-05	0.000857	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—C3—glaucoma	2.78e-05	0.000857	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Timolol—glaucoma	2.73e-05	0.000461	CcSEcCtD
Epoprostenol—Dizziness—Betaxolol—glaucoma	2.71e-05	0.000457	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—SMO—glaucoma	2.69e-05	0.00083	CbGpPWpGaD
Epoprostenol—Urticaria—Timolol—glaucoma	2.66e-05	0.000448	CcSEcCtD
Epoprostenol—Body temperature increased—Timolol—glaucoma	2.64e-05	0.000446	CcSEcCtD
Epoprostenol—Abdominal pain—Timolol—glaucoma	2.64e-05	0.000446	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—glaucoma	2.64e-05	0.000812	CbGpPWpGaD
Epoprostenol—Vomiting—Betaxolol—glaucoma	2.6e-05	0.000439	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—MMP1—glaucoma	2.6e-05	0.000801	CbGpPWpGaD
Epoprostenol—Rash—Betaxolol—glaucoma	2.58e-05	0.000435	CcSEcCtD
Epoprostenol—Dermatitis—Betaxolol—glaucoma	2.58e-05	0.000435	CcSEcCtD
Epoprostenol—Headache—Betaxolol—glaucoma	2.56e-05	0.000433	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—CAV1—glaucoma	2.49e-05	0.000768	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—SMO—glaucoma	2.48e-05	0.000764	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—SMO—glaucoma	2.48e-05	0.000764	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RPTOR—glaucoma	2.47e-05	0.000761	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Timolol—glaucoma	2.46e-05	0.000416	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GSTT1—glaucoma	2.45e-05	0.000754	CbGpPWpGaD
Epoprostenol—Nausea—Betaxolol—glaucoma	2.43e-05	0.00041	CcSEcCtD
Epoprostenol—Asthenia—Timolol—glaucoma	2.4e-05	0.000405	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—MMP1—glaucoma	2.39e-05	0.000738	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NCK2—glaucoma	2.39e-05	0.000737	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—FN1—glaucoma	2.37e-05	0.000731	CbGpPWpGaD
Epoprostenol—Pruritus—Timolol—glaucoma	2.37e-05	0.000399	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—GSTT1—glaucoma	2.31e-05	0.000713	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—CAV1—glaucoma	2.3e-05	0.000707	CbGpPWpGaD
Epoprostenol—Diarrhoea—Timolol—glaucoma	2.29e-05	0.000386	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—RPTOR—glaucoma	2.27e-05	0.0007	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RPTOR—glaucoma	2.27e-05	0.0007	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—glaucoma	2.23e-05	0.000688	CbGpPWpGaD
Epoprostenol—Dizziness—Timolol—glaucoma	2.21e-05	0.000373	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—NCK2—glaucoma	2.2e-05	0.000678	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NCK2—glaucoma	2.2e-05	0.000678	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—FN1—glaucoma	2.19e-05	0.000673	CbGpPWpGaD
Epoprostenol—Vomiting—Timolol—glaucoma	2.13e-05	0.000359	CcSEcCtD
Epoprostenol—Rash—Timolol—glaucoma	2.11e-05	0.000356	CcSEcCtD
Epoprostenol—Dermatitis—Timolol—glaucoma	2.11e-05	0.000355	CcSEcCtD
Epoprostenol—Headache—Timolol—glaucoma	2.09e-05	0.000353	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—HDAC9—glaucoma	2.03e-05	0.000627	CbGpPWpGaD
Epoprostenol—Nausea—Timolol—glaucoma	1.99e-05	0.000335	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.97e-05	0.000608	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN2B—glaucoma	1.96e-05	0.000605	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—EDN1—glaucoma	1.96e-05	0.000603	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ABCA1—glaucoma	1.95e-05	0.000601	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP1B1—glaucoma	1.95e-05	0.000601	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NOS3—glaucoma	1.89e-05	0.000581	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HDAC9—glaucoma	1.87e-05	0.000577	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HDAC9—glaucoma	1.87e-05	0.000577	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP1B1—glaucoma	1.84e-05	0.000568	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1B1—glaucoma	1.82e-05	0.00056	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—EDN1—glaucoma	1.8e-05	0.000555	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—EDN1—glaucoma	1.8e-05	0.000555	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EDN1—glaucoma	1.78e-05	0.000547	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NOS3—glaucoma	1.74e-05	0.000535	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CTSA—glaucoma	1.72e-05	0.000531	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—C3—glaucoma	1.71e-05	0.000526	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTHFR—glaucoma	1.65e-05	0.000507	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EDN1—glaucoma	1.64e-05	0.000504	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EDN1—glaucoma	1.64e-05	0.000504	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA5A—glaucoma	1.62e-05	0.0005	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NARFL—glaucoma	1.62e-05	0.0005	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SMO—glaucoma	1.59e-05	0.00049	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—C3—glaucoma	1.57e-05	0.000485	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—C3—glaucoma	1.57e-05	0.000485	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTM1—glaucoma	1.56e-05	0.000481	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—C3—glaucoma	1.55e-05	0.000478	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APOE—glaucoma	1.53e-05	0.000472	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CAV1—glaucoma	1.52e-05	0.000468	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTM1—glaucoma	1.47e-05	0.000454	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMO—glaucoma	1.47e-05	0.000451	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMO—glaucoma	1.47e-05	0.000451	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NTRK2—glaucoma	1.46e-05	0.000448	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTM1—glaucoma	1.45e-05	0.000448	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—C3—glaucoma	1.43e-05	0.00044	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—C3—glaucoma	1.43e-05	0.00044	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—BAD—glaucoma	1.43e-05	0.00044	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—MTHFR—glaucoma	1.38e-05	0.000425	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—glaucoma	1.36e-05	0.000419	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NTRK2—glaucoma	1.34e-05	0.000413	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NTRK2—glaucoma	1.34e-05	0.000413	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOE—glaucoma	1.28e-05	0.000395	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CAV1—glaucoma	1.27e-05	0.000392	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—glaucoma	1.25e-05	0.000385	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NGFR—glaucoma	1.25e-05	0.000385	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NTRK1—glaucoma	1.19e-05	0.000366	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NGFR—glaucoma	1.15e-05	0.000354	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NGFR—glaucoma	1.15e-05	0.000354	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOS3—glaucoma	1.15e-05	0.000354	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN2B—glaucoma	1.09e-05	0.000337	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NTRK1—glaucoma	1.09e-05	0.000336	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NTRK1—glaucoma	1.09e-05	0.000336	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—glaucoma	1.05e-05	0.000323	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EDN1—glaucoma	1.05e-05	0.000323	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—glaucoma	1.03e-05	0.000316	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN2B—glaucoma	1.01e-05	0.00031	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN2B—glaucoma	1.01e-05	0.00031	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1B—glaucoma	9.95e-06	0.000306	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EDN1—glaucoma	9.66e-06	0.000298	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EDN1—glaucoma	9.66e-06	0.000298	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NGF—glaucoma	9.65e-06	0.000297	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NOS3—glaucoma	9.62e-06	0.000296	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—glaucoma	9.45e-06	0.000291	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—C3—glaucoma	9.17e-06	0.000282	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NGF—glaucoma	8.88e-06	0.000273	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NGF—glaucoma	8.88e-06	0.000273	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—glaucoma	8.8e-06	0.000271	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—glaucoma	8.54e-06	0.000263	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CAV1—glaucoma	8.46e-06	0.000261	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—C3—glaucoma	8.44e-06	0.00026	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—C3—glaucoma	8.44e-06	0.00026	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FN1—glaucoma	8.05e-06	0.000248	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BAD—glaucoma	7.95e-06	0.000245	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA1—glaucoma	7.92e-06	0.000244	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—glaucoma	7.86e-06	0.000242	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—glaucoma	7.86e-06	0.000242	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CAV1—glaucoma	7.78e-06	0.00024	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CAV1—glaucoma	7.78e-06	0.00024	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CTSA—glaucoma	7.67e-06	0.000236	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FN1—glaucoma	7.41e-06	0.000228	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FN1—glaucoma	7.41e-06	0.000228	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BAD—glaucoma	7.32e-06	0.000225	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BAD—glaucoma	7.32e-06	0.000225	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA2—glaucoma	7.24e-06	0.000223	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	7.08e-06	0.000218	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	7.08e-06	0.000218	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—glaucoma	6.4e-06	0.000197	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—glaucoma	5.89e-06	0.000181	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—glaucoma	5.89e-06	0.000181	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—glaucoma	5.54e-06	0.000171	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—glaucoma	5.13e-06	0.000158	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TXN—glaucoma	5.1e-06	0.000157	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—glaucoma	5.1e-06	0.000157	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—glaucoma	5.1e-06	0.000157	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—glaucoma	4.72e-06	0.000145	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—glaucoma	4.72e-06	0.000145	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	4.66e-06	0.000143	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	4.61e-06	0.000142	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—glaucoma	4.61e-06	0.000142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—glaucoma	4.24e-06	0.000131	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—glaucoma	4.24e-06	0.000131	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—glaucoma	3.96e-06	0.000122	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—glaucoma	3.48e-06	0.000107	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—glaucoma	3.2e-06	9.87e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—glaucoma	3.2e-06	9.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.19e-06	9.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1B1—glaucoma	3.15e-06	9.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCA1—glaucoma	3.15e-06	9.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—glaucoma	2.52e-06	7.76e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—glaucoma	2.23e-06	6.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—glaucoma	2.07e-06	6.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAV1—glaucoma	2.06e-06	6.33e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—glaucoma	1.55e-06	4.79e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—glaucoma	1.42e-06	4.38e-05	CbGpPWpGaD
